Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484829 | 0.93 | NPY1R (0.42) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL30484834 | 0.93 | NPY4R (0.47) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL30484831 | 0.92 | NPY4R (0.46) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL29886546 | 0.92 | NMT1 (0.47) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL30484833 | 0.92 | NPY4R (0.44) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL29473686 | 0.90 | NMT2 (0.47) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL29611990 | 0.89 | ERAP2 (0.49) | MMENMT2NMT1ERAP2ERAP1 | |
| SCHEMBL29473693 | 0.88 | GRIN2D (0.44) | NMT2NMT1NPY1RNPY2RNPY4R | |
| SCHEMBL30900798 | 0.88 | ERAP2 (0.50) | MMEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30478747 | 0.87 | NMT2 (0.49) | MMENMT2NMT1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | disclosed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | MME 410/4885NMT2 1419/4885NMT1 1736/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | MME 2535/4885NMT2 1060/4885NMT1 1178/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | MME 761/4885NMT2 378/4885NMT1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.